AstraZeneca plc (AZN) Ordinary US$0.25

Sell:11,116.00pBuy:11,120.00pNo change

FTSE 100:0.66%
Market closed | Prices delayed by at least 15 minutes
Sell:11,116.00p
Buy:11,120.00p
Change:No change
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:11,116.00p
Buy:11,120.00p
Change:No change
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.

Key people

Pascal Soriot
Chief Executive Officer, Executive Director
Aradhana Sarin
Chief Financial Officer, Executive Director
Marc Dunoyer
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
Jeffrey A. Pott
Chief Human Resources Officer, Chief Compliance Officer, General Counsel
Sharon Barr
Executive Vice President - BioPharmaceuticals R&D
Pam P. Cheng
Executive Vice President - Global Operations, Information Technology and Chief Sustainability Officer
Ruud Dobber
Executive Vice President - BioPharmaceuticals Business Unit
David Fredrickson
Executive Vice President - Oncology Business Unit
Susan Galbraith
Executive Vice President - Oncology and Research and Development
Iskra Reic
Executive Vice President, International
Michel Demare
Non-Executive Independent Chairman of the Board
Birgit M. Conix
Non-Executive Director
Rene Haas
Non-Executive Director
Marcus Wallenberg
Non-Executive Director
Euan Ashley
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    AZN
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    GB0009895292
  • Market cap
    £172.63bn
  • Employees
    94,300
  • Shares in issue
    1.55bn
  • Exchange
    London Stock Exchange (LON)
  • Index
    FTSE All Share Index, FTSE 100 Index, SX All Share PI Market Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.